FORE Biotherapeutics Receives FDA Breakthrough Therapy Designation for Plixorafenib in Brain Cancer
FORE Biotherapeutics has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its investigational drug plixorafenib, developed for the treatment of adult patients with BRAF V600E-mutated high-grade glioma, a severe form of brain cancer.
The designation recognises the potential of plixorafenib to offer meaningful improvement over existing treatment options.
It also marks the first time a targeted therapy has received Breakthrough Therapy Designation for high-grade glioma, adding to previous Fast Track and Orphan Drug designations already granted for central nervous system (CNS) cancers.
Plixorafenib is a targeted BRAF inhibitor designed to address specific genetic alterations driving tumour growth.
It has shown early clinical activity in patients with primary brain and spinal cord tumours, including glioblastoma and other high-grade gliomas, based on data from early-stage clinical studies.
The FDA decision was supported by results from Phase 1/2a trials and an ongoing Phase 2 basket study. Early findings have shown encouraging response rates in selected patient groups, with continued evaluation underway to confirm longer-term outcomes.
The Breakthrough Therapy Designation is intended to speed up development and regulatory review, allowing closer interaction with the FDA and potential access to accelerated approval pathways.
FORE Biotherapeutics is continuing its Phase 2 FORTE basket study, with further results expected in the coming years to assess the drug’s safety and effectiveness across multiple BRAF-altered cancers.
